ASP2535 explained

ASP2535 is an inhibitor of the type 1 glycine transporter.^[1] It could potentially be used in treatment of Alzheimer's disease and schizophrenia.

Potential uses

ASP2535 has been investigated for the treatment of Alzheimer's disease and schizophrenia, it is able to inhibit the memory deficit induced by scopolamine, an anticholinergic agent. It could also be used for schizophrenia since lack of NMDA receptor activation has been linked to schizophrenia, since glycine is required as a co-agonist at N-methyl-D-aspartate receptors, higher glycine levels may be able to restore normal receptor function.^[2]

Notes and References

1. Harada . Katsuya . Nakato . Kazuhiro . Yarimizu . Junko . Yamazaki . Mayako . Morita . Masahiko . Takahashi . Shinji . Aota . Masaki . Saita . Kyoko . Doihara . Hitoshi . Sato . Yuichiro . Yamaji . Takayuki . Ni . Keni . Matsuoka . Nobuya . 2012-06-15 . A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease ]. European Journal of Pharmacology . 685 . 1–3 . 59–69 . 10.1016/j.ejphar.2012.04.013 . 1879-0712 . 22542656.
2. Dhami . Kamaldeep . MacKay . Marnie . Maia-de-Oliveira . Joao Paulo . Hallak . Jaime . Todd . Kathryn . Baker . Glen . Dursun . Serdar . June 2013 . Novel Targets for Development of Drugs for Treating Schizophrenia: Focus on Glycine, D-Serine and Nitric Oxide . Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology . en . 23 . 2 . 129–137 . 10.5455/bcp.20130629042437 . 1017-7833.